Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company focused on developing novel monoclonal and bispecific antibodies targeting Death Receptor 3 (DR3) for the treatment of inflammatory and immune-mediated diseases. The company's website is www.shattucklabs.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Shattuck Labs, Inc. does
In the company’s own words
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company focused on developing novel monoclonal and bispecific antibodies targeting Death Receptor 3 (DR3) for the treatment of inflammatory and immune-mediated diseases. The company's website is www.shattucklabs.com.
The company's lead product candidate, SL-325, is a high-affinity DR3 blocking monoclonal antibody designed to achieve more complete blockade of the clinically validated DR3/TL1A pathway compared to existing TL1A blocking antibodies. SL-325 represents a potentially first-in-class approach to targeting this pathway, with preclinical studies demonstrating superior binding characteristics and a favorable immunogenicity profile. The company is currently conducting a Phase 1 clinical trial evaluating SL-325 in healthy volunteers, with plans to initiate a Phase 2 trial in patients with Crohn's Disease in the third quarter of 2026.
Beyond SL-325, Shattuck Labs is developing SL-425, a half-life extended version of SL-325, which is undergoing chronic toxicology studies. The company is also advancing multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and other biologically relevant targets for inflammatory and immune-mediated diseases.
The company's competitive advantages stem from its expertise in protein engineering and TNF receptor biology, combined with a differentiated approach of targeting the DR3 receptor rather than its ligand TL1A. This strategy addresses key limitations observed with existing TL1A blocking antibodies, particularly regarding immunogenicity and durability of effect. Shattuck Labs manufactures its product candidates through third-party contract manufacturers using mammalian cell lines, with bulk drug substance currently produced by Kemwell Biopharma Private Limited.
The company operates in the large and growing inflammatory bowel disease market, which is projected to expand significantly over the coming years. Shattuck Labs competes against numerous established pharmaceutical and biotechnology companies developing therapies for immune-mediated diseases, though it remains the only company with publicly disclosed DR3-targeted blocking antibodies in development.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- AUSTIN, TX
- Fiscal year end
- December
- CIK
- 1680367
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Shattuck Labs, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Shattuck Labs, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Shattuck Labs, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Shattuck Labs, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Shattuck Labs, Inc.'s last four quarterly filings that the numbers alone won't show?”